

## **Annexure 1:**

**The following drugs are listed on WHO's Model List of Essential Medicines, 2025\***

Also, the lowest and highest prices (listed on the website of 1mg) are provided for 1 vial of most of the drugs.

1. **Rituximab**, for multiple sclerosis, Burkitt lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and follicular lymphoma (Rs. 12,175 to Rs. 40,650 per vial for 500 mg)
2. **Trastuzumab**, for early stage HER2-positive breast cancer, and for metastatic HER2-positive breast cancer (Rs. 6102 to Rs. 22,664 for a 150 mg injection)
3. **Pembrolizumab**, for metastatic cervical cancer, metastatic colorectal cancer, metastatic non-small cell lung cancer, and metastatic melanoma (Rs. 194,828 for a 4ml vial)
4. **Atoltivimab + Maftivimab + Odesivimab**, for ebola
5. **Adalimumab**, an immunomodulator for non-malignant disease, a medicine affecting skin differentiation and proliferation, juvenile joint diseases (Rs. 11,716 To Rs. 28,323 for a 40 mg injection)
6. **Blinatumomab**, immunomodulator
7. **Emicizumab**, a medicine affecting coagulation (Rs. 53,004 for a 30 mg injection)
8. **Ustekinumab**, a medicine affecting skin differentiation and proliferation (Rs. 93,829 for a 90 mg injection)
9. **Bevacizumab**, Anti-vascular endothelial growth factor (VEGF) (Rs. 4,994 to Rs. 30,473 for a 100 mg injection)

\* <https://iris.who.int/server/api/core/bitstreams/17642505-eed3-4940-a691-4f1dfa0d835a/content>